ATC Group: B01AX05 Fondaparinux

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of B01AX05 in the ATC hierarchy

Level Code Title
1 B Blood and blood forming organs
2 B01 Antithrombotic agents
3 B01A Antithrombotic agents
4 B01AX Other antithrombotic agents
5 B01AX05 Fondaparinux

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
PAREN - Parenteral 2.5 mg

Active ingredients in B01AX05

Active Ingredient Description
Fondaparinux

Fondaparinux is a synthetic and selective inhibitor of activated Factor X (Xa). The antithrombotic activity of fondaparinux is the result of antithrombin III (ATIII) mediated selective inhibition of Factor Xa.

Related product monographs

Title Information Source Document Type  
ARIXTRA Solution for injection European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Australia (AU)

Austria (AT)

Brazil (BR)

Canada (CA)

Croatia (HR)

Cyprus (CY)

Ecuador (EC)

Estonia (EE)

Finland (FI)

France (FR)

Hong Kong (HK)

Ireland (IE)

Israel (IL)

Japan (JP)

Lithuania (LT)

Mexico (MX)

Netherlands (NL)

Poland (PL)

Romania (RO)

Singapore (SG)

Spain (ES)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.